These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 6377570

  • 1. Antithrombogenic effects of calcium channel blockers: synergism with prostacyclin and thromboxane synthase inhibitors.
    Onoda JM, Sloane BF, Honn KV.
    Thromb Res; 1984 Jun 01; 34(5):367-78. PubMed ID: 6377570
    [Abstract] [Full Text] [Related]

  • 2. Inhibitory effects of endothelial cells and calcium channel blockers on platelet aggregation.
    Yamada Y, Furui H, Furumichi T, Suzuki T, Yamauchi K, Yokota M, Hayashi H, Saito H.
    Jpn Heart J; 1990 Mar 01; 31(2):201-15. PubMed ID: 2113109
    [Abstract] [Full Text] [Related]

  • 3. Disparate effects of the calcium-channel blockers, nifedipine and verapamil, on alpha 2-adrenergic receptors and thromboxane A2-induced aggregation of human platelets.
    Johnson GJ, Leis LA, Francis GS.
    Circulation; 1986 Apr 01; 73(4):847-54. PubMed ID: 3004784
    [Abstract] [Full Text] [Related]

  • 4. Adenosine potentiates the inhibitory effects of calcium channel antagonists on human platelet aggregation induced by thromboxane A2 or U46619.
    Johnson GJ, Leis LA, Francis GS.
    Thromb Res; 1990 Jul 01; 59(1):139-48. PubMed ID: 2399526
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of rabbit platelet phosphodiesterase activity and aggregation by calcium channel blockers.
    Moore JB, Fuller BL, Falotico R, Tolman EL.
    Thromb Res; 1985 Nov 01; 40(3):401-11. PubMed ID: 2417362
    [Abstract] [Full Text] [Related]

  • 6. The generation of TXA2 in human platelet rich plasma and its inhibition by nictindole and prostacyclin.
    Grodzińska L, Marcinkiewicz E.
    Pharmacol Res Commun; 1979 Feb 01; 11(2):133-46. PubMed ID: 375247
    [No Abstract] [Full Text] [Related]

  • 7. In vitro effects of two novel calcium antagonists (nitrendipine and nisoldipine) on intraplatelet calcium redistribution, platelet aggregation and thromboxane A2 formation. Comparison with diltiazem, nifedipine and verapamil.
    Rostagno C, Abbate R, Gensini GF, Coppo M, Prisco D, Boddi M, Neri Serneri GG.
    Thromb Res; 1991 Aug 15; 63(4):457-62. PubMed ID: 1754998
    [No Abstract] [Full Text] [Related]

  • 8. Effects of calcium channel blockers on platelet aggregation and thromboxane A2 formation: an in vivo double blind randomized study.
    Rostagno C, Prisco D, Paniccia R, Costanzo G, Poggesi L, Boddi M, Abbate R.
    Thromb Res; 1990 Aug 01; 59(3):531-9. PubMed ID: 2237825
    [Abstract] [Full Text] [Related]

  • 9. Effects of diltiazem and verapamil on ADP-induced rabbit platelet shape change and aggregation.
    Dehpour AR, Samadian T, Akhavan MM, Meysamee F, Delfan A.
    Gen Pharmacol; 1995 Oct 01; 26(6):1295-9. PubMed ID: 7590122
    [Abstract] [Full Text] [Related]

  • 10. Antiaggregatory activity of N-methyl- and N-isobutyl-1,2-diphenyl ethanolamines in rat platelets.
    el Tahir KE, el-Naser MA, Ageel AM, el-Obeid HA, al-Rashood KA.
    Arch Int Pharmacodyn Ther; 1990 Oct 01; 307():162-71. PubMed ID: 2095711
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of human platelet aggregation and cytoplasmic calcium response by calcium antagonists: studies with aequorin and quin2.
    Ware JA, Johnson PC, Smith M, Salzman EW.
    Circ Res; 1986 Jul 01; 59(1):39-42. PubMed ID: 3089642
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of platelet aggregation by diltiazem. Comparison with verapamil and nifedipine and inhibitory potencies of diltiazem metabolites.
    Kiyomoto A, Sasaki Y, Odawara A, Morita T.
    Circ Res; 1983 Feb 01; 52(2 Pt 2):I115-9. PubMed ID: 6831645
    [Abstract] [Full Text] [Related]

  • 13. Potentiation by dazoxiben, a thromboxane synthetase inhibitor, of platelet aggregation inhibitory activity of a thromboxane receptor antagonist and of prostacyclin.
    Bertele V, De Gaetano G.
    Eur J Pharmacol; 1982 Dec 03; 85(3-4):331-3. PubMed ID: 6295787
    [Abstract] [Full Text] [Related]

  • 14. An investigation into the effects of nifedipine and nimodipine on platelet function and vascular prostacyclin synthesis.
    Jeremy JY, Barradas MA, Mikhailidis DP, Dandona P.
    Drugs Exp Clin Res; 1985 Dec 03; 11(9):645-51. PubMed ID: 3939725
    [Abstract] [Full Text] [Related]

  • 15. Effects of dihydropyridines and inorganic calcium blockers on aggregation and on intracellular free calcium in platelets.
    Palés J, Palacios-Araus L, López A, Gual A.
    Biochim Biophys Acta; 1991 May 07; 1064(2):169-74. PubMed ID: 1645196
    [Abstract] [Full Text] [Related]

  • 16. Calcium blocker diltiazem inhibits platelet activation and stimulates vascular prostacyclin synthesis.
    Mehta J, Mehta P, Ostrowski N.
    Am J Med Sci; 1986 Jan 07; 291(1):20-4. PubMed ID: 3510543
    [Abstract] [Full Text] [Related]

  • 17. Influence of calcium-channel blockers on platelet function and arachidonic acid metabolism.
    Mehta JL.
    Am J Cardiol; 1985 Jan 25; 55(3):158B-164B. PubMed ID: 2982252
    [Abstract] [Full Text] [Related]

  • 18. Verapamil is a potent inhibitor of 5-HT-induced platelet aggregation.
    Glusa E, Bevan J, Heptinstall S.
    Thromb Res; 1989 Jul 15; 55(2):239-245. PubMed ID: 2528843
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of whole blood platelet aggregation by nicardipine, and synergism with prostacyclin in-vitro.
    Greer IA, Walker JJ, McLaren M, Calder AA, Forbes CD.
    Thromb Res; 1986 Feb 15; 41(4):509-18. PubMed ID: 3083526
    [Abstract] [Full Text] [Related]

  • 20. Calcium channel blocker treatment of tumor cells induces alterations in the cytoskeleton, mobility of the integrin alpha IIb beta 3 and tumor-cell-induced platelet aggregation.
    Timar J, Chopra H, Rong X, Hatfield JS, Fligiel SE, Onoda JM, Taylor JD, Honn KV.
    J Cancer Res Clin Oncol; 1992 Feb 15; 118(6):425-34. PubMed ID: 1377695
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.